Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P61278 (
somatostatin
)
22,083
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
In Parkinson's disease the progressive loss of nigrostriatal dopamine neurons leads to striatal dopamine deficiency and correlates with the severity of parkinsonian disability. The findings concerning dopamine receptors both in vitro and in vivo are not consistent, possibly reflecting differences in patient populations, but the presynaptic defect in dopaminergic neurotransmission is greater than that seen in postsynaptic receptor binding studies. The cholinergic neurons in the extrapyramidal nuclei are relatively well preserved, but subcortico-cortical and -hippocampal cholinergic neurons degenerate in relation to the degree of dementia. The decreased
GABA
receptor binding in the parkinsonian substantia nigra possibly reflects the loss of nigral dopamine neurons, since nigral
GABA
receptors are located on these neurons. Of the various neuropeptides, the concentration of met- and leu-enkephalin seems to be reduced in the striatum. In the substantia nigra the concentration of substance P decreases, together with the met-enkephalin and cholecystokinin levels. The concentration of
somatostatin
decreases in the frontal cortex and hippocampus of demented patients. With the exception of the association between cortical
somatostatin
deficiency and intellectual deterioration, the role of the neuropeptides in the pathophysiology and clinical features of Parkinson's disease are not yet fully understood.
...
PMID:Chemical neurotransmission in the parkinsonian brain. 282 31
The study of neurotransmitter receptors aids in the understanding of the normal anatomy, pharmacology, therapeutics and pathophysiology of disease processes involving the basal ganglia. Receptors may be studied in vitro by homogenate binding experiments, enzyme analysis or quantitative autoradiography and in vivo with positron emission tomography. In the substantia nigra (SN), receptors have been identified for
somatostatin
, neurotensin, substance P, glycine, benzodiazepine and
GABA
, opiates, dopamine, angiotensin converting enzyme (ACE) and serotonin. The striatum has receptors for dopamine,
GABA
and benzodiazepines, acetylcholine, opiates, substance P, glutamate and cholecystokinin.
GABA
and benzodiazepine receptors are also located in the globus pallidus. In Parkinson's disease, striatal dopamine D-2 receptors are elevated in patients that have not received L-DOPA therapy. This supersensitivity is reversed with agonist therapy. Muscarinic binding to cholinergic receptors seems to correlate with dopamine receptors. Delta opiate receptors are increased in the caudate and mu binding is reduced in the striatum. In the SN of patients with Parkinson's disease, there is reduced binding of
somatostatin
, neurotensin, mu and kappa opiates, benzodiazepine and
GABA
and glycine. In Huntington's disease, there is reduced binding of
GABA
and benzodiazepines, dopamine, acetylcholine, glutamate and CCK. There is increased binding of
GABA
in both the SN and globus pallidus. Glycine binding is increased in the substantia nigra and ACE is reduced.
...
PMID:Receptors in the basal ganglia. 282 9
The functional role of three putative neurotransmitter systems in the visual cortex is compared; the GABAergic inhibitory interneurons, the interneurones containing
somatostatin
and the cholinergic input originating from the nucleus basalis of Meynert (nbM). Evidence is presented to support the role of GABAergic processes in the generation of the functional structure of the visual cortex and the view that the cholinergic input exerts a neuromodulatory influence enhancing stimulus selective responses. Although the neuropeptide
somatostatin
produces facilitatory and inhibitory effects on visual cortical cells there is no clear functional pattern to its action. The possible significance of this data and the interaction of SSt with
GABA
is discussed in the light of evidence that they may coexist in some cells.
...
PMID:Modulatory and inhibitory processes in the visual cortex. 286 40
Immunohistochemical studies with antisera to
somatostatin
have, in many instances, led the way to our present understanding of the peptidergic nervous system.
Somatostatin
was among the first of the hypophysiotropic hormones shown to be contained in diverse neuronal circuits outside of the hypothalamus. For example,
somatostatin
is found within neurons ranging in location from the cerebral cortex to primary sensory neurons to enteric neurons within the gut wall.
Somatostatin
was also the first neuropeptide demonstrated to coexist within vertebrate neurons that also produce a classical neurotransmitter. Since this initial demonstration in sympathetic ganglionic neurons,
somatostatin
and numerous other neuropeptides have been demonstrated to coexist with a variety of classical neurotransmitters. The "rules" for coexistence are not clear, since
somatostatin
coexist in some instances with norepinephrine, in other cases with
GABA
, and probably with other classical transmitters as well. In some neurons,
somatostatin
also coexists with certain other neuropeptides. Finally, the specificity of immunohistochemical localizations of
somatostatin
has now been confirmed by virtue of the co-staining of
somatostatin
neurons with antisera to other portions of the biosynthetic precursor to
somatostatin
.
...
PMID:Immunocytochemical studies of somatostatin neurons in brain. 286 29
Studies carried out in the years since William Beaumont's direct observations of gastric motility have provided increased understanding of the physiological roles of the stomach and of the mechanisms for the regulation of gastric motility. Tonic contractions of the proximal stomach are of primary importance for transfer of liquids from the stomach to the duodenum. Peristaltic contractions of the distal stomach are of primary importance for reducing the size of solid food particles and for transfer of solids to the duodenum. Because gastric emptying requires a net antral-duodenal pressure gradient, contractions of the duodenum also influence the rate of gastric emptying. Gastrointestinal hormones, including gastrin, cholecystokinin, secretin,
somatostatin
, and others, are released by contact of chyme with the intestinal mucosa, and affect contractions of the proximal stomach, distal stomach, and duodenum. Neural reflexes that arise from the stomach act through autonomic motor nerves to allow regulation by the central nervous system of gastric motility.
gamma-Aminobutyric acid
, opioids, and bombesin may serve as central neurochemical regulators of gastric motility.
...
PMID:Regulation of gastric emptying. 286 73
The ability of certain neuropeptides (glucagon,
somatostatin
, leu-enkephalin and neurotensin) to release known neurotransmitters (glycine,
GABA
, dopamine and 5-hydroxytryptamine) was tested in the chicken retina. Tritiated neurotransmitters were injected intravitreally in chicken eyes. After excision, the retina was stimulated in vitro with the neuropeptide in micromolar concentrations while monitoring the efflux of radioactivity from the retina. A rise of the efflux represents a stimulus dependent release. Neurotensin release [3H] glycine, [3H]dopamine and [3H]5-hydroxytryptamine. Leu-enkephalin released [3H]dopamine and
somatostatin
released [3H]5-hydroxytryptamine. Glucagon was without effect. [3H]
GABA
was not released by any of the neuropeptides.
...
PMID:Neurotransmitter release by certain neuropeptides in the chicken retina. 286 56
We examined the effects of cholinergic, peptidergic and GABAergic agents on secretin secretion from canine duodenal mucosal explants incubated in organ culture media. Carbachol (10(-12) to 10(-4) M), atropine (10(-6) to 10(-4) M), hexamethonium (10(-6) to 10(-4) M), and
somatostatin
did not alter basal secretion of secretin.
Somatostatin
(10(-7) to 10(-8) M) inhibited secretin secretion stimulated by pH 4.5. Met, Leu and their D-ala2-analogs inhibited both basal and pH 4.5-stimulated secretin. Naloxone reversed the inhibition caused by met-enkephalin at pH 7.4.
GABA
(10(-9) to 10(-6) M) stimulated both basal and pH 4.5-stimulated secretin secretion.
GABA
-stimulated secretin secretion was neuronal in nature, bicuculline sensitive and was mediated via post ganglionic cholinergic neurons.
GABA
-stimulated secretin secretion was inhibited by both
somatostatin
and metenkephalin, suggesting that
GABA
-stimulated secretin secretion may be under the inhibitory control of peptidergic agents as well.
...
PMID:Neurohormonal regulation of secretin secretion in canine duodenal mucosa in vitro. 287 46
gamma-Aminobutyric acid
(
GABA
) is found in high concentrations in the pancreatic islet. In addition, enzymes regulating the level of
GABA
(L-glutamate decarboxylase and GABA-alpha-ketoglutarate transaminase) have been immunohistochemically localized in the medullary cells of the islet. In this study, an immunofluorescence and elution/restaining protocol is used to determine the distribution of
GABA
and either insulin, glucagon, or
somatostatin
in a tissue section.
GABA
was not detected within the islet alpha- or delta-cells but was determined to be localized within the insulin-containing beta-cells.
...
PMID:Immunohistochemical colocalization of GABA and insulin in beta-cells of rat islet. 287 11
While the dentate gyrus is clearly the simplest of the cortical fields that constitute the hippocampal formation, it nonetheless occupies a pivotal position in the flow of information through this region. Though it has been the subject of anatomical study for over a century and its major connections have been known for almost as long, the use of newly developed histochemical and immunohistochemical techniques have demonstrated many new facets of its intrinsic connectivity and afferent innervation. These techniques have established that it is innervated by cholinergic, noradrenergic, serotonergic and dopaminergic fibers. More recent studies have shown that fibers and cell bodies of the dentate gyrus are immunoreactive for variety of neuroactive substances including the excitatory amino acids glutamate and aspartate, the inhibitory transmitter
GABA
, as well as peptides of many types including the opioid peptides, enkephalin and dynorphin, several forms of
somatostatin
, neuropeptide Y, cholycystokinin, vasoactive intestinal peptide and substance P. In this review, we will briefly summarize the distribution of each of these putative transmitter systems within the dentate gyrus. The perspective emerges that the plethora of newly identified and chemically specific fiber systems enriches the classical understanding of the organization of this relatively simple cortical structure. Since there is thus far no evidence for the exclusion from the dentate gyrus of any class of transmitter bearing fiber or neuron found in the neocortex, it can be viewed as a relatively simple model system for studying the interactions of specific transmitter systems in a laminated, cortical structure.
...
PMID:Transmitter systems in the primate dentate gyrus. 287 75
CSF neurotransmitter markers may reflect neurochemical alterations in Alzheimer's disease (AD). The best studied neurochemical deficit in AD is that of acetylcholine. Both acetylcholinesterase and butyrylcholinesterase activity have been reported to be reduced in some but not all studies of AD CSF. Studies of monoamine metabolites have also been controversial but most authors have found reduced concentrations of CSF HVA, lesser reductions in HIAA and no change in MHPG. CSF
GABA
concentrations have been found to be reduced in AD. Studies of CSF neuropeptides in AD have shown reduced concentrations of
somatostatin
and vasopressin, normal concentrations of vasoactive intestinal polypeptide and either normal or decreased concentrations of beta-endorphin and corticotropin releasing factor. Although no individual CSF neurochemical markers are specific for AD it may be possible to develop a profile of several neurochemical markers which will have enhanced specificity.
...
PMID:CSF neurotransmitter markers in Alzheimer's disease. 287 17
<< Previous
1
2
3
4
5
6
7
8
9
10
Next >>